Akarso Bio develops a zero-calorie, clean-label prebiotic fiber platform that naturally stimulates GLP-1. This versatile ingredient helps food and beverage brands create products that enhance satiety, improve gut health, and support metabolic wellness. The platform enables manufacturers to innovate cost-effectively with functional ingredients that meet accelerating consumer demand.
Funding
Funding not disclosed
Founders
Product
Problem
Developing novel therapeutic candidates for complex diseases presents significant challenges in identifying effective drug targets and optimizing preclinical development pathways. This often leads to lengthy R&D cycles and a lack of viable treatment options for patients with unmet medical needs.
Solution
Akarso Bio is focused on advancing the discovery and development of innovative therapeutics. The company leverages proprietary computational biology platforms to identify novel drug targets and design candidate molecules with enhanced efficacy and safety profiles. By integrating advanced bioinformatics and molecular modeling, Akarso Bio aims to accelerate the preclinical pipeline and deliver differentiated therapeutic candidates for challenging disease indications. This approach is designed to de-risk early-stage drug development and increase the probability of clinical success.
Target Audience
Akarso Bio's primary customers are pharmaceutical and biotechnology companies seeking to augment their R&D pipelines with novel therapeutic candidates and innovative drug discovery technologies.
Features
- Proprietary computational biology platform for target identification and validation
- AI-driven molecular design and optimization for novel therapeutic candidates
- In silico screening and ADMET property prediction to de-risk preclinical development
- Focus on complex diseases with significant unmet medical needs
- Integrated approach to drug discovery and preclinical candidate selection